FULC supply chain intelligence for Fulcrum Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CAMP4-THERAPEUTICS-CORP | CAMP4-THERAPEUTICS-CORP | 92% | Fulcrum made an undisclosed upfront non-refundable, non-creditable payment to CAMP4. |
| CAMP4 | CAMP4 | 90% | We are responsible for the costs associated with the development and regulatory approvals of licensed products. |
| SANOFI | SANOFI | 90% | the Company granted Sanofi an exclusive license to commercialize losmapimod, an oral small molecule for the treatment of facioscapulohumeral muscular dystrophy, outside of the United States |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 85% | the Company obtained a worldwide exclusive license to certain intellectual property related to CAMP4's Diamond-Blackfan anemia program |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 85% | Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: the Company obtained a worldwide exclusive license to certain intellectual property related to CAMP4's Diamond-Blackf… |
| GSK | GSK plc | 80% | GSK granted us a right of reference to certain INDs filed |
| GSK | GSK plc | 80% | Reciprocal relationship from GSK graph: Reciprocal relationship from FULC graph: GSK granted us a right of reference to certain INDs filed |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SANOFI | SANOFI | 90% | we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod for the treatment of FSHD outside of the United States. |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from FULC graph: Reciprocal relationship from BMY graph: Reciprocal relationship from FULC graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 72% | nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of December 31, 2024, … |
| BMYMP | Bristol-Myers Squibb Co | 72% | nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. As of December 31, 2024, … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from FULC graph: nable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned le… |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 72% | nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the notice by the Company. F- 20 million, which was allocated to the performance oblig… |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | 72% | Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: Reciprocal relationship from CAMP graph: Reciprocal relationship from FULC graph: nce with the agreement, the termina… |
| SNYNF | Sanofi | 72% | nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the notice by the Company. F- 20 million, which was allocated to the performance oblig… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: nce with the agreement, the termination became effective on , which is 120 days following the date of receipt of the… |
| MEDICAL-CENTER-CORPORATION | MEDICAL-CENTER-CORPORATION | 62% | may be reduced in specified circumstances. The MyoKardia Collaboration Agreement continues on a country-by-country and product-by-product basis until the last to expire royalty term for a product, at… |
| PRESENTATION-FULCRUM-THERAPEUTICS-INC | PRESENTATION-FULCRUM-THERAPEUTICS-INC | 62% | n received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the progress of the studies or extent of services provided and there… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| FULC-DEBT-9680 | Warrants outstanding: 850000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| FULC-DEBT-9681 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2019-12-31. |
| FULC-DEBT | Debt stack $5.9M | 90% | Market cache reports total debt of $5.9M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| FULC-OWNER-SUVRETTA-CAPITAL-MANAGEMENT-LLC | SUVRETTA CAPITAL MANAGEMENT, LLC | 90% | 13F overlay lists SUVRETTA CAPITAL MANAGEMENT, LLC as top holder; 168 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 |